Pear Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Pear Therapeutics, Inc.

Pear Therapeutics, Inc. was a U.S.-based digital health company focused on prescription digital therapeutics, or software-based treatments designed to complement or, in some cases, replace parts of traditional care pathways. The company was listed on the U.S. NASDAQ market under the ticker PEAR, and it was headquartered in Boston, Massachusetts, United States. Boston was a logical base for the business given its proximity to the life sciences, biotech, and healthcare innovation ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm?utm_source=openai)) Pear emerged as one of the early pioneers in prescription digital therapeutics, building its investment case around FDA-authorized software therapies. That regulatory moat mattered because the category was still relatively new, clinically specialized, and reimbursement-sensitive. In December 2021, the post-business-combination company began trading on the Nasdaq Capital Market under the PEAR symbol. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556722000041/pear_2022investordaypres.htm?utm_source=openai)) The company’s commercial portfolio centered on three FDA-authorized products. reSET was designed for substance use disorder, reSET-O targeted opioid use disorder in combination with buprenorphine, and Somryst addressed chronic insomnia. Pear marketed these products alongside PearMD, a clinician-facing dashboard intended to support monitoring, engagement, and integration into care delivery. From a competitive standpoint, Pear positioned itself as a category creator and first mover, with some of the earliest FDA-authorized PDTs in the market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm?utm_source=openai)) Geographically, Pear was primarily a U.S. commercial story. Its core commercialization efforts were concentrated in the United States, although its filings also referenced limited international reach, including authorization for reSET in Singapore. The company relied on access agreements with health systems, payers, state agencies, and other healthcare stakeholders, while continuing to navigate the broader challenge of payer coverage, physician adoption, and patient utilization that typically shapes the economics of digital therapeutics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm?utm_source=openai)) The most important recent development was highly material and negative for equity investors: on April 7, 2023, Pear announced that it had filed for Chapter 11 bankruptcy protection in the United States with the intention to sell its assets. Before that filing, the company had already withdrawn revenue and operating guidance and initiated a strategic review aimed at maximizing shareholder value. In practical terms, that means PEAR should be viewed through a restructuring lens rather than as a normal operating growth equity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000020/peartherapeuticsfilesforch.htm?utm_source=openai))